The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Genetic dynamics and factors predictive of survival in relapsed AML
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the genetic dynamics and factors predictive of survival in patients with acute myeloid leukemia (AML) at first relapse. Dr Bataller highlights that some mutations were more likely to persist at first relapse, and the choice of chemotherapy impacted the genetic dynamics of a patient. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
